Unlike ordinary wellness products, Saba GLP-1 is carefully formulated to support multiple aspects of metabolic health in one convenient supplement
Semaglutide is not a quick fix
And do these drugs tell us anything new about the biology of addiction
The first was a multi-center study that used data from 33,021 participants and found that GLP-1/GIP agonist and SGLT2 inhibitor use were associated with comparable rates of new retinopathy development and worsening of existing nonproliferative retinopathy
Endocrinology 140: 1687-1694, 1999
GLP-1 agonists were originally approved to treat Type 2 Diabetes (T2D) but their most recent incarnations, which consist of both next generation GLP-1s and combinations (Ozempic, Mounjaro, Wegovy, Zepbound), have moved beyond the realm of T2D into the treatment of obesity